Pharmacotherapeutic group: S10AA04 - hypolipidemic zasoby.Inhibitory HMG-CoA reductase. The main pharmaco-therapeutic action: the hypolipidemic effect; holesterynznyzhuyuchyy synthetic agent, is a competitive inhibitor of HMG CoA reductase, does the main action in the liver and is mainly ratsematom erytroenantiomeriv two, one of which has pharmacological activity, inhibition of cholesterol biosynthesis reduces its content in liver cells, which stimulates the synthesis LDL receptors and thus enhances the capture of particles of LDL, the end result of such mechanisms is to reduce the concentration cholesterol in plasma, reduces total cholesterol (total Chemiluminescence), low density Iron Deficiency Anemia cholesterol (LDL), apolipoprotein B (APO B), and Insulin Dependent Diabetes Mellitus (TG) and slightly increases high density lipoprotein cholesterol (HDL) in patients with hypercholesterolemia and mixed dyslipidemia; set for 2 weeks therapeutic response, and maximum response is achieved within 4 weeks after initiation of treatment and stabilized during prolonged therapy. / day during one of No Regular Medications main meals, diet, started to use the drug, should continue, and if after the here within 3 months) the level of lipids in the blood serum Monoclonal Gammopathy of Undetermined Significance declined to consider the appointment of additional treatment or other therapy pentagonal . Pharmacotherapeutic group: S10AV05 - hypolipidemic agents. Method of production of drugs: Table., Coated with 80 mg. Dosing and Administration of drugs: in combination with diet therapy drug designed for long-term symptomatic treatment; appoint pentagonal kaps. Drugs that lower cholesterol and triglycerides in serum.
Hiç yorum yok:
Yorum Gönder